Observational studyCardiovascular diabetology2013
Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
Observational study in Cardiovascular diabetology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Effects of Allisartan on Uric Acid, Left Atrial, Left Ventricular, and Artery Stiffness in Mild-to-Moderate Essential Hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2025Trial
- Trial
- Effect of losartan combined with amlodipine or with a thiazide on uric acid levels in hypertensive patients.Therapeutic advances in cardiovascular disease · 2017Trial
- Effect of sacubitril/valsartan on serum uric acid and blood pressure in patients with hypertension and asymptomatic hyperuricemia: A randomized clinical trial.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Effect of sodium-glucose cotransporter-2 inhibitors on uric acid in patients with heart failure and preserved ejection fraction: a retrospective analysis in real word.BMC cardiovascular disorders · 2026Article
- Factors influencing serum uric acid levels and their impact on cardiovascular risk in patients with pediatric chronic kidney disease.Pediatric nephrology (Berlin, Germany) · 2026Article
- Firsekibart for steroid withdrawal in glucocorticoid-dependent refractory gout: a case report.Frontiers in immunology · 2026Article
- Correlations of serum uric acid, fibrinogen and homocysteine levels with carotid atherosclerosis in hypertensive patients.Frontiers in cardiovascular medicine · 2025Article
- Long-term benefit of SGLT2 inhibitors to prevent heart failure hospitalization in patients with diabetes, with potential time-varying benefit.Clinical and translational science · 2024Article
- Lowering and Raising Serum Urate Levels: Off-Label Effects of Commonly Used Medications.Mayo Clinic proceedings · 2022Review
- Evaluation of the prognostic ability of serum uric acid for elderly acute coronary syndrome patients with diabetes mellitus: a prospective cohort study.Journal of Zhejiang University. Science. B · 2021Article
- Article
- Impact of hyperuricemia on mortality related to aortic diseases: a 3.8-year nationwide community-based cohort study.Scientific reports · 2020Article
- Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus.BMC pharmacology & toxicology · 2020Article
- Assessment of effect modification of statins on new-onset diabetes based on various medical backgrounds: a retrospective cohort study.BMC pharmacology & toxicology · 2019Article
- Modulation of brain ACE and ACE2 may be a promising protective strategy against cerebral ischemia/reperfusion injury: an experimental trial in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2018Article
- Comparative Effect of Calcium Channel Blockers on Glomerular Function in Hypertensive Patients with Diabetes Mellitus.Drugs in R&D · 2017Article
- A Comparative Effectiveness Study of Renal Parameters Between Imidapril and Amlodipine in Patients with Hypertension: A Retrospective Cohort Study.Cardiology and therapy · 2017Article
- Azilsartan, an angiotensin II type 1 receptor blocker, restores endothelial function by reducing vascular inflammation and by increasing the phosphorylation ratio Ser(1177)/Thr(497) of endothelial nitric oxide synthase in diabetic mice.Cardiovascular diabetology · 2014Article
- Effects of irbesartan on serum uric acid levels in patients with hypertension and diabetes.Clinical pharmacology : advances and applications · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAngiotensin II type 1 receptor blockers (ARB) are a frequently used class of antihypertensive drug. The ARB losartan is known to decrease the serum uric acid (SUA) level. However, there are very few clinical data comparing the effects of other ARBs on SUA level under the conditions of clinical practice. This study evaluated and compared the long-term effects of monotherapy with five ARBs on SUA level in Japanese hypertensive patients with type 2 diabetes mellitus (DM).
methodsWe identified hypertensive patients with type 2 DM who had been treated with monotherapy with losartan (n = 214), valsartan (n = 266), telmisartan (n = 185), candesartan (n = 458), or olmesartan (n = 192), in whom laboratory data of SUA between November 1, 2004 and July 31, 2011 were available, from the Nihon University School of Medicine's Clinical Data Warehouse (NUSM's CDW). We used a propensity-score weighting method and a multivariate regression model to adjust for differences in the background among ARB users, and compared the SUA level. The mean exposure of losartan was 264.7 days, valsartan 245.3 days, telmisartan 235.9 days, candesartan 248.9 days, and olmesartan 234.5 days.
resultsIn losartan users, mean SUA level was significantly decreased from baseline, while it was conversely increased in users of other ARBs; valsartan, telmisartan, candesartan, and olmesartan. The mean reduction of SUA level from baseline was significantly greater in losartan users compared with that in other ARB users. Comparison of ARBs other than losartan showed no significant difference in mean change in SUA level from baseline.
conclusionsOur study showed that losartan had the most beneficial effect on SUA level among five ARBs, and that there was no significant difference in the unfavorable effects on SUA level among four ARBs other than losartan, at least during one year. These findings provide evidence of an effect of ARBs on SUA level, and support the benefit of the use of losartan in hypertensive patients with type 2 DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.